Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson’s Disease
Objective: To investigate the effect of exogenous ketone ester supplementation on motor and non-motor symptoms in Parkinson’s Disease (PD). Background: Animal research and human pilot…The mitochondrial targeted drug SBT-272 attenuates dopaminergic neuron loss, alpha-synuclein burden and neuroinflammation in a mouse model of Parkinson’s Disease
Objective: To assess the preclinical efficacy of the investigational drug SBT-272 in a mouse model of Parkinson’s Disease (PD). Background: SBT-272 is a peptidomimetic drug…Validation of the Neuroprotective Potential of SLP-2 against alpha-synuclein neuropathology in a Mouse Model of Parkinson’s Disease
Objective: We aim to validate the neuroprotective potential of SLP-2 against α-syn neuropathology and neurodegeneration of dopaminergic neurons in a mouse model of Parkinson’s disease.…Molecular investigation of apparently healthy heterozygous Parkin mutation carriers
Objective: To investigate whether apparently healthy individuals carrying a heterozygous pathogenic Parkin (PRKN) mutation show molecular phenotypes of mitochondrial dysfunction. Background: Homozygous or compound-heterozygous mutations…Metabolic alterations in a Drosophila model of Parkinson’s disease
Objective: Identification of metabolic alterations that could be contributing to Parkinson’s disease (PD) physiopathology and become new biomarkers or therapeutic targets for the disease. Background:…Reduced cerebral energy metabolism in Parkinson’s disease in contrast to Progressive Supranuclear Palsy
Objective: To determine the significance of 31P-MRSI to differentiate between idiopathic Parkinson’s disease (PD), Progressive supranuclear palsy (PSP), and healthy control subjects. Background: Bioenergetic disturbances,…Relationship of subcortical iron deposition and mitochondrial dysfunction in patients with idiopathic Parkinson’s disease
Objective: To investigate subcortical brain iron deposition as a potential predictor of the bioenergetic status in patients with idiopathic Parkinson's disease. Background: The underlying pathophysiology…PARK2 p.Ala82Glu variant is not associated with Parkinson’s disease
Objective: The aim of the study was to analyze potential pathogenicity of the PARK2 p.Ala82Glu mutation, by functional studies of Parkin in the mitophagy paradigm…Loss of CHCHD2 and CHCHD10 disrupts mitochondrial cristae phenocopying patient mutations
Objective: Characterization of novel of a novel CHCHD2 (C2) and CHCHD10 (C10) knockout mouse model. Background: Dominant mutations in the mitochondrial paralogs CHCHD2 (C2) and…Poly-ADP-ribose polymerase 1 modulates mitochondrial fission via LRRK2 in a rotenone-induced Parkinson’s disease model
Objective: To clarity the effects and mechanism of poly-ADP-ribose polymerase 1(PARP1) in regulating mitochondrial fusion/fission in a rotenone-induced Parkinson's disease (PD) model. Background: Accumulating evidences…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »